Global CD47 Inhibitor Drug Clinical Trial Report 2022-2028: Magrolimab Developed by GlaxoSmithKline is One of the Most Promising CD47 Targeting Antibodies in Clinical Development

DUBLIN , Aug. 24, 2022 /PRNewswire/ -- The "Global CD47 Inhibitor Drug Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

The global CD47 market opportunity is expected to surpass US$ 2 Billion by 2028

This is mainly due to large number of clinical pipeline products which are expected to gain approval and their encouraging response in the management of cancer. Further, the huge investments by pharmaceutical giants and special designations also suggest the promising growth of the market.

Immunotherapy particularly with immune checkpoint inhibitors has shown to transform the global cancer therapeutics market. However, despite these huge advancements in the field of cancer therapeutics, the majority of patients does not respond to or develop resistance to immunotherapy, highlighting the need for additional approaches to expand cancer immunotherapy.

In the last few years, technological advancements have enabled the identification of various other receptors which can be of therapeutic potential. Recently, CD47 has gained the major focus of researchers as a therapeutic potential target for drug development.

Till date, no CD47 targeting antibody has gained market authorization. However, the pipeline is highly crowded indicating encouraging role of CD47 targeting therapies in the management of cancer. Magrolimab developed by GlaxoSmithKline is one of the most promising CD47 targeting antibodies in clinical development.

Currently, the company is evaluating the drug in a phase-III clinical trial accessing the efficacy and safety of Magrolimab in combination with azacitidine for the management of acute myeloid leukemia and myelodysplastic syndrome. The drug has received fast-track designation from US FDA and is expected to enter the market by 2024.

Apart from this, several other pharmaceutical giants have developed a robust clinical pipeline of the CD47 targeting therapies which are being evaluated in various phase-I/II clinical trials. The companies have also adopted strategic alliances such as collaboration, partnership, or acquisitions to maintain their competitive edge in the market.

For instance, AbbVie entered into collaboration with I-Mab for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

To further enhance the therapeutic potential of CD47 targeting therapies, researchers have also initiated clinical trials evaluating their role in combination therapies. For instance, Arch Oncology and Merck are currently conducting phase-I/II clinical trial to evaluate AO-176, the Company's novel anti-CD47 antibody in combination with Keytruda for the treatment of patients with select solid tumors including relapsed, platinum-resistant ovarian cancer, endometrial cancer, and gastroesophageal cancer.

Another, ALX Oncology in collaboration with Eli Lilly to evaluate the combination of ALX148, a next-generation CD47 blocker, and Cyramza for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. It is suggested that combination therapies will dominate the global market owing to their enhanced efficacy and specificity towards cancer cells.

US and Chinese pharmaceutical firms are currently dominating the CD47 inhibitors drugs RandD landscape driven by encouraging clinical pipeline, increasing cancer research activities to find innovative therapies, and favorable government policy framework.

For instance, in 2022, US FDA granted orphan drug designation to AO-176 for the management of relapsed or refractory multiple myeloma. AO-173 is an investigational CD47 targeting monoclonal antibody developed by Arch Oncology.

Another, ALX Oncology has also received orphan drug designation for evorpacept for the treatment of patients with acute myeloid leukemia. The orphan drug designation is associated with incentives that favor the rapid approval of the drug in the region.

Report Highlights:

• CD47 Inhibitor Drug Market Trends and Future Prospects
• Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials
• Orphan, Fast Track, Breakthrough Therapy Designation Insight
• Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials
• CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication and Phase
• CD47 Inhibitors Drug Clinical Trials Insight As Mono and Combination Therapy
• Global CD47 Inhibitor Drug Market Dynamics

Key Topics Covered:

1. CD 47 as Novel Cancer Immunotherapy Target

2. Ongoing Anti-CD47 Agents in Clinical Trials
2.1 CD47 Targeting Monoclonal Antibodies
2.2 CD47 Targeting Bispecific Antibodies

3. Current Market Trends & Future Prospects

4. Global CD47 Inhibitors Drug Clinical Pipeline Overview
4.1 By Country
4.2 By Company
4.3 By Indication
4.4 By Phase

5. Global CD47 Inhibitors Drug Clinical Pipeline By Company, Indication & Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Phase-II/III
5.7 Phase-III

6. Global CD47 Inhibitor Drug Market Dynamics
6.1 Key Factors Driving CD47 Inhibitor Clinical Trials
6.2 Clinical & Technological Challenges

7. Competitive Landscape
7.1 Adagene
7.2 Alector
7.3 ALX Oncology
7.4 Beta Pharma
7.5 Biocad
7.6 ImmuneOncia Therapeutics
7.7 ImmuneOnco Biopharma
7.8 Light Chain Bioscience
7.9 Phanes Therapeutics
7.10 Virtuoso Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/ekivou

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets